LSU Health Shreveport is bringing testing online that will allow them to check a person’s blood for antibodies that may indicate they are immune to coronavirus.
The School of Graduate Studies offers PhD degrees in five programs, an MS degree in Biomedical Science, and a combined MD-PhD degree program. Successful applicants can enter directly into one the five programs or can enter though the Interdisciplinary Graduate Program in which students choose a mentor and program after the first semester.
The School of Graduate Studies was established as part of the LSU Medical Center (known as LSU Health Shreveport today) in 1965, with degrees offered in five basic science departments. The first class was accepted in 1974 and the first PhD degree awarded in 1978. On March 25, 2004, the Louisiana Board of Regents approved administrative separation of the School of Graduate Studies in Shreveport from the School of Graduate Studies in New Orleans. The School of Graduate Studies in Shreveport was placed under the leadership of the LSUHS Chancellor in 2004. Dr. Sandra Roerig was appointed the first Dean of the school on April 1, 2004 and served in this role until her retirement in 2017.
Working with supportive faculty mentors, our students are prepared to become biomedical scientists, contributing to advances in healthcare and biotechnology, and educators, training the next generation of basic scientists, physicians and other healthcare professionals. Learn more about our Student Achievement.
Scientists at LSU Health Shreveport continue to have a significant impact on the fight against COVID-19 in Louisiana with their latest achievement being able to offer serology testing to support the Convalescent Plasma Therapy clinical trial and help identify ideal plasma donors.
Phase two in the fight against COVID-19 is ramping up. The fight began with testing, now it's the race to find a treatment and eventually a vaccine. Convalescent plasma is so far showing great promise.
LSU Health Shreveport has become one of the leaders in the fight against COVID-19, through its healthcare services, testing and innovative research.The work likely will earn the medical facility a place in the history books as 2020 will undoubtedly be known as the year of the coronavirus.
The Shreveport Times reached out to Professor Andrew Yurochko, Carroll Feist endowed chair of viral oncology and department vice-chair of microbiology and immunology, LSUHS, with the Emerging Viral Threat lab which began processing COVID-19 samples last Wednesday.
LSU Health Shreveport has established the Emerging Viral Threat (EVT) Laboratory to address the need for faster detection and processing of COVID-19 tests.
LSUHS leadership, faculty, staff, students and community supporters recently honored the continued growth of research initiatives and funding at the second annual Research Celebration event held on February 25, 2020.
Internationally recognized for his research on inflammatory vascular pathology, specifically on and the relationship between inflammation and vascular growth and function, Dr. Kevil discovered detailed mechanistic relationships between angiogenesis and inflammation.
Aphios Granted U.S. Patent for Oral Administration of Bryostatin-1 Nanoparticles for Treatment of Neurodegenerative Diseases, which was co-invented by LSU Health Shreveport professor, Dr. J. Steven Alexander.
JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD), TV1001SR, which was invented by LSU Health Shreveport professor and vice chancellor for research, Dr. Chris Kevil.